Contrave fluctuates obesity treatment market led by Belviq

Like the last year’s Belviq, new obesity treatments approved by the FDA are expected to fluctuate the domestic obesity treatment market.

According to the Ministry of Food and Drug Safety on the 2^nd, Kwang Dong Pharmaceutical’s diet pill, ‘Contrave ER Tab(naltrexone+bupropion),’ was domestically approved. Thus, it is expected to be launched soon.

Contrave is a new drug introduced by Kwang Dong...